Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC)
Version of Record online: 2 DEC 2013
© 2013 The Authors. BJU International © 2013 BJU International
Special Issue: Focus on Urological Oncology
Volume 113, Issue 5b, pages E62–E66, May 2014
How to Cite
de Martino, M., Waldert, M., Haitel, A., Schatzl, G., Shariat, S. F. and Klatte, T. (2014), Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC). BJU International, 113: E62–E66. doi: 10.1111/bju.12436
- Issue online: 23 APR 2014
- Version of Record online: 2 DEC 2013
- Accepted manuscript online: 5 SEP 2013 07:01AM EST
- blood group;
- blood type;
- To evaluate ABO blood group as a prognostic marker in patients with renal cell carcinoma (RCC).
Patients and Methods
- This retrospective study included 556 consecutive patients who underwent surgery for RCC at a single institution.
- The associations of ABO blood group with clinical and pathological variables were assessed using Kruskal–Wallis and chi-squared tests.
- The impact on overall survival (OS) and RCC-specific survival (RCC-SS) was analysed using univariable and multivariable Cox proportional hazards regression models.
- Blood group O was associated with the absence of lymph node metastases (P = 0.034) and the presence of bilateral RCC (P = 0.017).
- No associations with age, gender, body mass index, Charlson comorbidity index, T stage, M stage, grade and histological subtype were observed.
- In univariable and multivariable survival analysis, ABO blood group was not associated with OS and RCC-SS.
- In the present study, ABO blood group was not linked with RCC prognosis.
- Blood group O may be associated with the absence of lymph node metastases and the presence of bilateral RCC.
- External validation in larger cohorts is necessary.